

Oxular announces 4th UK Patent issued related to its proprietary Ocular Drug Delivery Device and Drug Compositions”

13 November 2019 – Oxular Limited, the Oxford-based retinal therapeutics company, today announced the UK Intellectual Property Office granted GB-B-2548988 in a patent titled “Ophthalmic delivery device and ophthalmic drug compositions.”

GB-B-2548988 provides for a cannulation device that enables an active agent containing composition to be administered and directed toward the posterior retina region of the suprachoroidal space from an anterior tissue access site such as the pars plana. The cannulation device is also described to have utility to deliver an active agent containing composition to a specific site in the eye to treat a local condition such as a tumor. The invention provides methods of treatment of an ocular disease or condition accordingly and describes drug containing compositions for use with the device.

We strongly believe this ocular drug delivery technology and companion drug compositions enables Oxular’s unique treatment approach which aims to access specific small spaces in the eye and to provide unique drug distribution to tissues specifically involved in retinal diseases. The drug delivery device is paired, and companion sustained release drug compositions form a complete system which is engineered to meet the demands of current market trends toward longer treatment durations and less invasive delivery.

Enquiries

Ben Atwell

Tel: +44 (0) 2037 271390

About Oxular Limited

Oxular is developing novel retinal treatments engineered to access specific small spaces in the eye and to provide unique drug distribution to tissues specifically involved in retinal diseases. The innovative approach aims to increase therapeutic effectiveness, reduce side-effects and minimize frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications (www.oxular.com).